Literature DB >> 18720404

Glycodelin reduces breast cancer xenograft growth in vivo.

Laura C Hautala1, Riitta Koistinen, Markku Seppälä, Ralf Bützow, Ulf-Håkan Stenman, Pirjo Laakkonen, Hannu Koistinen.   

Abstract

Malignant growth is characterized by loss of cell differentiation, uncontrolled proliferation and resistance to apoptosis. Many tumor suppressor genes that protect cells against malignant transformation regulate cell differentiation. Here, we show for the first time that glycodelin, a differentiation-related protein, reduces breast cancer tumor growth in vivo. We found that glycodelin cDNA-transfected MCF-7 breast cancer cells showed a differentiated phenotype and produced smaller tumors in mouse mammary fat pads compared with control-transfected cells. Glycodelin-induced differentiation was associated with reduced expression of oncogenes and increased expression of tumor suppressor genes. Our results suggest that glycodelin acts as a tumor suppressor in breast cancer. This may explain its reported association with a more favorable prognosis in some cancers. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18720404     DOI: 10.1002/ijc.23773

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Overexpression of the progestagen-associated endometrial protein gene is associated with microphthalmia-associated transcription factor in human melanoma.

Authors:  Suping Ren; Paul M Howell; Ying Han; Jiexi Wang; Minxia Liu; Yan Wang; Guobo Quan; Wei Du; Lei Fang; Adam I Riker
Journal:  Ochsner J       Date:  2011

Review 2.  The Roles of Glycodelin in Cancer Development and Progression.

Authors:  Juan Cui; Yanguo Liu; Xiuwen Wang
Journal:  Front Immunol       Date:  2017-11-29       Impact factor: 7.561

Review 3.  β-Lactoglobulin and Glycodelin: Two Sides of the Same Coin?

Authors:  Lindsay Sawyer
Journal:  Front Physiol       Date:  2021-05-20       Impact factor: 4.566

4.  PIAS1 regulates breast tumorigenesis through selective epigenetic gene silencing.

Authors:  Bin Liu; Samuel Tahk; Kathleen M Yee; Randy Yang; Yonghui Yang; Ryan Mackie; Cary Hsu; Vasili Chernishof; Neil O'Brien; Yusheng Jin; Guoping Fan; Timothy F Lane; Jianyu Rao; Dennis Slamon; Ke Shuai
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

5.  Functional characterization of the progestagen-associated endometrial protein gene in human melanoma.

Authors:  Suping Ren; Suhu Liu; Paul M Howell; Guangyu Zhang; Lewis Pannell; Rajeev Samant; Lalita Shevde-Samant; J Allan Tucker; Oystein Fodstad; Adam I Riker
Journal:  J Cell Mol Med       Date:  2009-10-03       Impact factor: 5.310

6.  Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer.

Authors:  Miriam Lenhard; Sabine Heublein; Christiane Kunert-Keil; Thomas Vrekoussis; Isabel Lomba; Nina Ditsch; Doris Mayr; Klaus Friese; Udo Jeschke
Journal:  BMC Cancer       Date:  2013-12-30       Impact factor: 4.430

7.  Altered glycosylation of glycodelin in endometrial carcinoma.

Authors:  Laura C Hautala; Poh-Choo Pang; Aristotelis Antonopoulos; Annukka Pasanen; Cheuk-Lun Lee; Philip C N Chiu; William S B Yeung; Mikko Loukovaara; Ralf Bützow; Stuart M Haslam; Anne Dell; Hannu Koistinen
Journal:  Lab Invest       Date:  2020-03-23       Impact factor: 5.662

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.